

23 October 2023

Bonus Issue of Options and Other Corporate Updates

Melodiol Global Health Limited (ASX:ME1) ('Melodiol' or 'the Company') is pleased to announce a pro-rata non-renounceable bonus issue of options to eligible shareholders on the basis of one (1) option ("Bonus Option") for every twenty (20) fully paid ordinary shares ("Shares") held on the Record Date, with the Bonus Option to be issued for nil consideration ("Bonus Offer"). The record date for the Bonus Offer is anticipated to be in early November 2023 ("Record Date").

The purpose of the Bonus Offer is to recognise the support and loyalty the Company has received from its shareholders to date, especially in the backdrop of challenging macro market conditions.

The Bonus Offer is being made to all shareholders of the Company named on its register of members at the Record Date, whose registered address is in Australia, New Zealand, or any other jurisdictions to whom the Company decides to make the Bonus Offer ("Eligible Shareholders").

The Bonus Options will be exercisable at \$0.01 on or before 5:00pm (WST) on the date that is five years from the date of issue. The Company will seek official quotation of the Bonus Options on the ASX.

Based on the number of Shares on issue at the date of this announcement, a total of 160,564,889 Bonus Options will be issued pursuant to the Bonus Offer. For the purpose of calculating each Eligible Shareholder's entitlement, fractional entitlements will be rounded down to the nearest whole number.

Full details of the Bonus Offer will be set out in a prospectus to be lodged by the Company on the ASX in early November 2023.

Other Corporate Updates

May Placement Update

Additionally, the Company provides the following update in respect of the placement undertaken in May 2023 (refer to ASX announcement dated 19 May 2023). The Company advises that one participant, who committed to providing \$350,900 has yet to provide funds to the Company. The Company has persistently attempted to enforce that the investor comply with their obligations, however given the length of time that has passed, the Company now considers that it is unlikely to receive this commitment and therefore updates the market as such.

-Ends-

Authority and Contact Details

This announcement has been authorised for release by the Board of Directors of Melodiol Global Health Limited.

For further information, please contact:

Investor Enquiries

Melodiol Global Health Limited

E: info@cresopharma.com

P: +61 (0) 497 571 532

About Melodiol

Melodiol Global Health Limited (ASX:ME1) brings the best of cannabis and other plant-based products to better the lives of people and animals. Melodiol strives for the highest quality in its products. It develops cannabis, hemp-derived and other plant based therapeutic, nutraceutical, and lifestyle products with wide consumer reach.

To learn more please visit: <https://melodiolglobalhealth.com/>

Melodiol offices:

Australia: Suite 5 CPC, 145 Stirling Hwy, Nedlands, WA, 6009

Canada: 59 Payzant Drive, Windsor, Nova Scotia, B0N 2T0 and 50 Ivey Ln, Windsor, Nova Scotia, B0N 2T0

Forward Looking statements

This announcement contains forward-looking statements with respect to Melodiol and its respective operations, strategy, investments, financial performance and condition.

These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Melodiol could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Melodiol and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Melodiol has no obligation to up-date such statements, except to the extent required by applicable laws.